Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study
Journal of Clinical Medicine · 27.07.2023 · 12 (15) · 4937
DOI: 10.3390/jcm12154937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.07.2023. Verfasst von Roya Abolfazli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran 11457-65111, Iran. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Orchid Pharmed Company.
Abstract (Originalsprache)
Background
This study evaluates the real-world safety and discontinuation rate of Zadiva® (generic product of dimethyl fumarate (DMF)) in Iranian patients with relapsing–remitting multiple sclerosis (RRMS), supplementing existing clinical evidence from randomized controlled trials.
Methods
This retrospective observational study evaluated the real-world safety and discontinuation rate of DMF in RRMS patients from Amir A’lam referral hospital’s neurology clinic. Data on safety, discontinuation rate, and clinical disease activity were collected retrospectively. The study aimed to assess the discontinuation rate, safety, and reasons for discontinuation, as well as the number of patients experiencing a relapse, MRI activity, and EDSS scores.
Results
In total, 142 RRMS patients receiving DMF were included in the study, with 15 discontinuing treatment due to adverse events, lack of efficacy, or pregnancy. Notably, a significant reduction in relapse rates was observed, with 90.8% of patients remaining relapse-free throughout the study period. After 1 year of treatment with Zadiva®, only 17.6% of patients experienced MRI activity, whereas the EDSS score remained stable.
Conclusions
This study provides important real-world data on the safety and tolerability of Zadiva® in RRMS patients. The results indicate that Zadiva® is generally well tolerated and safe, with a low discontinuation rate due to adverse events or lack of efficacy. These findings suggest that Zadiva® is an effective and safe treatment option for RRMS patients in real-world practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran 11457-65111, Iran.
- Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran 19978-66837, Iran.
- Food Industry Engineering, Tehran Islamic Azad University of Medical Sciences, Tehran 19395-1495, Iran.
- Department of Medical, Orchid Pharmed Company, Tehran 19947-66411, Iran.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Unverstät zu Berlin, Experimental and Clinical Research Center, 13125 Berlin, Germany.
- Department of Regional Health Research and Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.
ORCID-Profile: Sara Samadzadeh
Förderung
- Orchid Pharmed Company
Zitieren
APA
Abolfazli, R., Sahraian, M. A., Tayebi, A., Kafi, H., & Samadzadeh, S. (2023). Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study. Journal of Clinical Medicine, 12(15), 4937. https://doi.org/10.3390/jcm12154937
Vancouver
Abolfazli R, Sahraian MA, Tayebi A, Kafi H, Samadzadeh S. Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study. Journal of Clinical Medicine. 2023;12(15):4937. doi:10.3390/jcm12154937
BibTeX
@article{Abolfazli2023,
author = {Abolfazli, Roya and Sahraian, Mohammad Ali and Tayebi, Atefeh and Kafi, Hamidreza and Samadzadeh, Sara},
title = {Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {15},
pages = {4937},
doi = {10.3390/jcm12154937}
}
EUVIMED